The FDA has approved Sylvester Comprehensive Cancer Center–backed pancreatic cancer pill daraxonrasib, a milestone for patients with limited options in pancreatic oncology. The approval was reported alongside findings from the program’s broader research portfolio, including ctDNA blood testing and work on resistance dynamics, tying the new therapy to emerging biomarker and sequencing strategies. Separate regulatory headwinds are also emerging in immuno-oncology manufacturing. A Dutch court ordered Merck to stop manufacturing and selling its injectable formulation of Keytruda in eight European countries after finding Halozyme patent infringement, a decision that could affect supply and formulary planning while the dispute plays out. Together, the FDA authorization and the court-ordered manufacturing pause highlight a high-stakes moment for oncology drug access—where approval timing, IP enforcement, and downstream availability can move quickly and unevenly across geographies.